Learn more about Hexima’s technology.


Hexima is conducting a phase I/IIa clinical trial of its lead antifungal molecule, HXP124, as a treatment for fungal nail infections.

Latest news

Notice of Extraordinary Meeting & Proxy Form

Please be advised that Hexima Limited (Company) will be holding an Extraordinary General Meeting (EGM) at 11:00am (AEST) on Monday, 5 October 2020 via an audio webcast. Registration will commence at 10:30am. Please see meeting materials below. Meeting materials (pdf)...

Update on Hexima’s development program

Dear Shareholder, I am writing to you to provide an update on Hexima’s development program. Hexima’s lead product (HXP124) is a topical treatment for nail fungus (onychomycosis). HXP124 is an easy to apply solution that is simply painted onto nails, not requiring any...

Closing Share Price at 30 June 2020

Shares in Hexima Limited are not traded on the ASX.  The last off-market transfer of shares registered by the Company, as at the close of business on 30 June 2020, was at the price of $0.08 per share. Download a copy of this announcement (pdf)  

AGM 2019 – Presentation and Results

Presentations and Results from the 2019 Hexima Limited Annual General Meeting held 19 November 2019. AGM 2019 Chairman’s Address AGM 2019 CEO Presentation AGM 2019 Meeting Results

External Links

Take a look at these useful links to learn more about our industry.

Australian Academy of Science
Australian Science Media Centre logo